1 Intravenous iron therapy with ferric carboxymaltose results in a rapid and sustained rise in

- myocardial iron content through a non-canonical pathway: a translational study 2
- 3
- Vera-Aviles M^{1*}, Kabir S^{1*}, Shah A^{2*}, Polzella P^{3*}, Lim Y¹, Buckley P¹, Ball C¹, Swinkels D⁴, Matlung H⁵, 4
- Blans C⁵, Holdship P⁶, Nugent J⁷, Andreson E⁷, Desborough M³, Piechnik S⁸, Ferreira V⁸, Lakhal-5
- Littleton S¹ 6
- 7 ¹ Department of Physiology, Anatomy & Genetics, University of Oxford
- 8 ² Nuffield Department of Clinical Neurosciences, University of Oxford
- 9 ³ Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust.
- 10 ⁴ Iron Expertise Centre, Department of Laboratory Medicine, Radboud university medical centre,
- Nijmegen, Netherlands & Iron Expertise Centre, Sanquin Blood Bank, Amsterdam, Netherlands 11
- 12 ⁵ Sanguin Diagnostic Services, Amsterdam, Netherlands & Sanguin Research and Landsteiner
- Laboratory, Amsterdam, Netherlands 13
- ⁶ Department of Earth Sciences, University of Oxford 14
- ⁷ Department of Chemistry, University of Oxford 15
- 16 ⁸ Oxford Centre for Clinical Magnetic Resonance Research (OCMR), University of Oxford
- 17 *Equal contribution
- 18
- Correspondence: Prof S Lakhal-Littleton, Department of Physiology, Anatomy & Genetics, 19
- Sherrington Building, Parks Road, Oxford, OX1 3PT samira.lakhal-littleton@dpag.ox.ac.uk 20

21

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

22 ABSTRACT

23 Background and Aims

- 24 Intravenous iron therapies contain iron-carbohydrate complexes, designed to ensure iron becomes
- 25 bioavailable via the intermediary of spleen and liver reticuloendothelial macrophages. How other
- tissues obtain and handle this iron remains unknown. This study addresses this question in the
- 27 context of the heart.

28 Methods

- 29 A prospective observational study was conducted in 12 patients receiving ferric carboxymaltose
- 30 (FCM) for iron deficiency. Myocardial, spleen and liver magnetic resonance relaxation times, and
- 31 plasma iron markers were collected longitudinally. To examine the handling of iron taken up by the
- 32 myocardium, intracellular labile iron pool (LIP) was imaged in FCM-treated mice and cells.

33 Results

- 34 In patients, myocardial relaxation time T1 dropped maximally 3hrs post FCM, remaining low 42 days
- later, while splenic T1 dropped maximally at 14 days, recovering by 42 days. In plasma, non-
- 36 transferrin bound iron (NTBI) peaked at 3hrs, while ferritin peaked at 14 days. Changes in liver T1
- 37 diverged amongst patients. In mice, myocardial LIP rose 1h and remained elevated 42 days after
- 38 FCM. In cardiomyocytes, FCM exposure raised LIP rapidly. This was prevented by inhibitors of NTBI
- 39 transporters T-type and L-Type calcium channels and divalent metal transporter 1.

40 Conclusions

- 41 Intravenous iron therapy with FCM delivers iron to the myocardium rapidly through NTBI
- 42 transporters, independently of reticuloendothelial macrophages. This iron remains labile for weeks,
- 43 reflecting the myocardium's limited iron storage capacity. These findings challenge current notions
- 44 of how the heart obtains iron from these therapies and highlight the potential for long-term dosing
- 45 to cause cumulative iron build-up in the heart.

46 KEYWORDS

- 47 Intravenous iron therapy
- 48 Myocardium
- 49 Labile iron
- 50 Non-transferrin bound iron
- 51 Ferric carboxymaltose
- 52 Magnetic resonance
- 53

54 TRANSLATIONAL PERSPECTIVE

- Many patients now receive long-term IV iron therapy. The finding that a single standard
 dose of IV iron causes a sustained rise in myocardial iron underscores the risk for cumulative
 build-up to occur with multiple doses. Magnetic resonance monitoring of myocardial iron
 may be required to safeguard against progression towards pathological myocardial iron
 overload in these patients.
- Plasma ferritin levels reflect the iron content of reticuloendothelial macrophages. The
 finding that myocardial iron elevation following IV iron therapy is independent from
 reticuloendothelial macrophages highlights the limitations of using plasma ferritin cut-offs to
 safeguard against the risk of tissue iron overload.
- 64

65 **INTRODUCTION**

66 Iron deficiency ID is the commonest nutritional deficiency worldwide and is associated with adverse 67 outcomes in a broad range of settings¹⁻¹². Thus, tackling ID efficiently and safely holds the potential 68 to deliver cross-cutting benefits to large numbers of patients. ID has been traditionally treated with 69 oral iron supplements, which replenish iron incrementally over weeks by delivering ~100mg doses 70 into the gut lumen, of which typically 10 to 22% is absorbed into the circulation ¹³. Oral iron's 71 gastrointestinal side effects, poor compliance and limited absorption in inflammatory settings have fuelled a gradual shift towards intravenous iron therapies¹⁴⁻¹⁸. These can deliver up to 2000mg of 72 73 iron into the circulation at once. To minimise the otherwise toxic effects of free iron, the iron in IV 74 iron therapies is contained within carbohydrate complexes¹⁸. These are designed for targeted uptake 75 by macrophages of the reticuloendothelial system, in the spleen and to a lesser extent in the liver¹⁸⁻ 76 ²⁰. According to the consensus canonical pathway of IV iron metabolism, the iron-carbohydrate 77 complex is degraded within the lysosome, iron freed, exported into the circulation and loaded onto the plasma iron chaperone transferrin ¹⁸⁻²⁰. The iron made bioavailable through this pathway is 78 79 considered safe, because the transferrin-bound iron is non-reactive and only taken up by tissues 80 according to their needs. Indeed, surface expression of transferrin receptor (TfR) is coupled to 81 cellular iron need, because its translation is controlled by the iron homeostatic proteins Iron 82 Regulatory Proteins (IRPs)²¹. Inside cells, labile iron is quickly made non-reactive through storage into ferritin, the translation of which is also controlled by IRPs²¹. Because plasma ferritin derives primarily 83 from macrophages, uptake of iron-carbohydrate complexes by reticuloendothelial macrophages is 84 closely followed by a rise in plasma ferritin ²²⁻²³. 85

Pharmacokinetic studies have reported a rapid rise in plasma non-transferrin bound iron (NTBI)
 following treatment with intravenous iron, indicating that some iron is released from the

 24 N/bet remains unknown is whether the singulation 24 N/bet remains unknown is whether the

carbohydrate complex directly into the circulation ²⁴. What remains unknown is whether this NTBI is
 taken up by tissues, and the extent to which such uptake contributes to the ultimate rise in tissue

taken up by tissues, and the extent to which such uptake contributes to the ultimate rise in tissue
iron content resulting from intravenous iron therapy. This is an important question because, unlike

91 transferrin-bound iron, NTBI enters cells via non-canonical pathways that are not coupled to cellular

92 iron need²⁵. Because NTBI transporters are not regulated by IRPs, they continue to take up iron

93 despite excess cellular labile iron²⁵. The heart is particularly prone to NTBI uptake due to abundant

94 expression of certain NTBI transporters including L-type and T-type calcium channels (LTCCs, TTCCs)

95 and divalent metal transporter 1 (DMT1)^{26,27}. This, together with the heart's relatively limited

96 capacity to store labile iron into ferritin explain why iron overload cardiomyopathy is a frequent and

97 fatal complication in hemochromatosis and β -thalassaemia²⁸⁻³⁰.

- 98 Tissue iron uptake can be assessed non-invasively by magnetic resonance (MR) because the
- 99 ferromagnetic properties of iron influence certain MR tissue characteristics, in particular relaxation
- 100 times T1, T2, and T2^{*31}. Furthermore, the handling of iron taken up into tissues can be assessed
- 101 through reporter systems that rely on labile iron reactivity³². Using these approaches, the objective
- 102 of the current study is to investigate myocardial uptake and handling of iron following intravenous
- 103 iron therapy with the most widely used formulation ferric farboxymaltose (FCM, Ferinject[®]).

104 <u>METHODS</u>

105 This report was prepared according to STROBE and ARRIVE guidelines.

106 Clinical Study Design

- 107 <u>Study of Tissue Iron Uptake in Iron-deficient patients following intravenous iron therapy</u> (STUDY) is
- 108 an investigator-initiated, prospective, observational study conducted at one UK site, sponsored by
- the University of Oxford. The full study protocol is available in Supplemental File 3. The trial protocol
- and amendments were approved by a NHS ethics committee in the UK (North West Liverpool
- 111 Central Research Ethics Committee Ref: 22/NW/0172), and the Health Research Authority. The study
- 112 was registered prospectively on the ISRCTN registry (ISRCTN15770553) and clinicaltrials.gov
- 113 (NCT05609318). The sample size of 12 participants was not arrived at statistically, due to lack of
- previous information on the magnitude of acute effects of FCM on T1/T2/T2* values. Instead, the
- sample size of 12 was selected based on a previous exploratory study of MRI imaging following
- 116 intravenous infusion with ultrasmall superparamagnetic particles of iron oxide (USPIO), which used
- sample sizes of 5-12 participants per group³³.

118 Patients

- 119 Patients were recruited through the Iron Deficiency Management Service, part of the Oxford
- 120 University Hospitals NHS Foundation Trust (OUHFT). Patients, aged 18 years or above, scheduled to
- 121 receive intravenous iron therapy as per standard clinical care for correction of iron deficiency
- 122 (ferritin less than 100mcg/L and/or transferrin saturation less than 20%) with or without anaemia
- 123 (haemoglobin less than 120g/L for women and less than 130g/L for men) were invited to participate.
- 124 All eligible patients identified during the screening period were contacted. Following written
- 125 informed consent, patients were screened for exclusion criteria, which were any of the following:
- any MRI incompatible implants, pregnant or lactating participants, acute decompensated heart
- 127 failure, unstable clinical status, any other medical conditions which would influence the reliability of
- 128 the study results as determined by the investigators, any other contraindication to MRI. The full list
- 129 of inclusion and exclusion criteria is provided within the study protocol in Supplemental File.

130 Study Procedures

- A flow chart outlining study procedures is shown in Appendix A of study protocol in SupplementalFile.
- The full CMR protocol (including the standard Siemens printout) and mapping methods are providedin supplemental File.
- 135 FCM solution (Ferinject[®] [FCM], Vifor Pharma, Glattbrugg, Switzerland) was given as a 20-mL
- 136 intravenous infusion (equivalent to 1000 mg of iron) diluted in a sterile saline solution (0.9% wt/vol
- 137 NaCl) and administered over 15 minutes. Participants were closely monitored for signs of
- 138 hypersensitivity during the infusion and for at least 30 min after the treatment, as per standard
- 139 clinical care.

140 Study Outcomes

- Primary outcome- Changes from baseline in multi-organ magnetic resonance relaxation times T1, T2and T2* for each participant.
- 143 Secondary outcome- Change from baseline in plasma iron indices: iron, ferritin, transferrin
- saturation Tsat, non-transferrin bound iron NTBI, and serum levels of lipid peroxidation marker
- 145 malondialdehyde MDA

146 **Mice**

- 147 All animal procedures were compliant with the UK Home Office Animals (Scientific Procedures) Act
- 148 1986 (licence# P84F13B1B) and approved by the University of Oxford Medical Sciences Division
- 149 Ethical Review Committee. Bioluminescence studies used B6;FVB-Ptprca Tg(CAG-luc,-
- 150 GFP)L2G85Chco Thy1a/J mice (JAX strain #025854), which harbour the firefly luciferase transgene
- under control of CAG promoter; composed of human cytomegalovirus immediate early promoter
- enhancer with chicken beta-actin/rabbit beta-globin hybrid promoter. These mice have previously
- been characterised as having bioluminescence in the heart, spleen, muscle, pancreas, skin, thymus
- and bone marrow, but not in mature erythrocytes³⁶. Mice were housed under standard conditions
- in individually-ventilated cages with enrichment at a density of 2-4 animals per cage. A priori
- 156 humane endpoints were weight loss ≥15%, or signs of ill health (hunched posture and reduced
- activity) that did not resolve within 24 hours. Each animal represents an experimental unit. Allanimals were given an identifier code, to allow blinding during the conduct and analysis of
- animals were given an identifier code, to allow blinding during the conduct and analysis of
 experiments. Power calculations were not used due to lack of previous data on myocardial LIP.
- 160 Manipulation of iron status in mice
- 161 Mice heterozygous for luciferase transgene were randomly assigned to a standard iron-replete diet
- 162 containing 200 ppm iron (n=22), or an iron-deficient diet containing 5 ppm iron (n=25) (Teklad
- 163 TD.99397), which were provided for 6 weeks.
- 164 Within each dietary group, mice were then randomly assigned to receive a 100ul injection via the tail
- vein of either saline (n=11 for iron-replete diet, n=12 for iron-deficient diet) or iron as ferric
- 166 carboxymaltose (Ferinject[®] [FCM], Vifor Pharma, Glattbrugg, Switzerland) at 15mg/kg (n=11 for iron-
- 167 replete group, n=13 for iron-deficient group). Mice were used for bioluminescence imaging either 1
- 168 hour or 42 days post infusion. To minimise any potential confounding effects of age and sex, all
- animals entered the diary protocol at 6 weeks of age, and block randomisation was used to ensure
- balanced numbers of males and females in each group. Randomisation into diets and treatments
- 171 was carried out using the Rand() function in excel.

172 Labile iron imaging in murine hearts

- 173 Bioluminescence studies used the iron-caged luciferin described previously³².
- 174 Mice were anaesthetised using 2% isoflurane in O₂, and injected via the tail vein with 25nmoles of
- iron-caged luciferin (ICL-1) dissolved in 100ul saline. One minute later, the chest cavity was opened,
- and the heart immediately surgically excised, washed in ice-cold PBS to remove any blood clots, and
- 177 placed on a petri dish within the IVIS Lumina system. Bioluminescence imaging was performed in an
- 178 IVIS LUMINA II system, with small binning and F stop 1 settings. Bioluminescence signal was
- 179 collected for at least 2 minutes, with auto settings. Luminescence data were extracted using Living
- 180 Image Software4.7.3. First, a non-luminescence photograph was used to generate ROIs, by manually
- drawing around the outline of each heart (excluding atria). ROIs corresponding to individual hearts

- 182 were automatically propagated onto the luminescence sequence, and average radiance extracted
- 183 from each ROI as p/s/cm²/sr (photons, per second, per square cm, per steradian). The mean of the
- average radiance values acquired over in the first two minutes were calculated for each heart.
- 185 Following removal of the heart, blood was immediately collected from the chest cavity for Hb
- measurement and preparation of serum. Spleens and livers were also removed, washed in ice-cold
 PBS before snap-freezing for quantitation of total iron content.
- 187 PBS before snap-freezing for quantitation of total iron content.
- 188 No animals were lost to humane endpoints. However, some animals did not undergo myocardial LIP
- 189 imaging due to failure to infuse ICL-1 intravenously prior to imaging. Their spleens and livers were
- 190 still harvested for direct iron quantitation.

191 Iron quantitation in murine tissues

- 192 Snap-frozen livers and spleens were crushed on liquid nitrogen, and a minimum of 5mg digested in
- 193 nitric acid using a CEM microwave system. Elemental component analysis was carried out using
- 194 induced couple plasma mass spectrometry ICP-MS as per previous studies ³⁷. Values are normalised
- 195 to tissue weight.

196 Cardiac myocytes

- 197 For in-vitro bioluminescence studies, the rat cardiac myocyte cell line H9C2 (ATCC CRL1446, cardiac
- 198 myoblasts from rat) was transfected with Firefly Luiferase-eGFP Lentivirus (Tetubio, product
- reference #14979980) and positive selection was maintained by inclusion of Geneticin in growth
- 200 media. Transfected cells were maintained in complete Dulbecco's Modified Eagle's Medium (DMEM)
- 201 growth medium, supplemented with 10% fetal bovine serum (FBS) in standard tissue culture
- 202 conditions.

203 Labile iron imaging in cultured cardiac myocytes

- 204 Cells were plated in complete media in opaque 96 well plates at 50000cells/well overnight. To 205 eliminate any confounding effects of existing iron in FBS, growth media were changed to FBS-free
- 206 DMEM media two hours before treatment with sterile saline or FCM, still in FBS-free media. The
- amount of FCM added to the FBS-free media were determined as follows; as the standard human
- 208 FCM dose is 15mg iron/Kg, and the average plasma volume in humans is 60ml/Kg, the concentration
- of iron delivered to human plasma following a standard FCM dose is 0.25mg/mL. Thus FCM was
- added to the FBS-free growth media at a concentration of 0.25mg iron/mL to mimic the standard
- 211 human dose.
- 212 Prior to imaging, saline and FCM-containing media were removed, cells washed with PBS, then ICL-1
- 213 added at 100uM to each well, and plates imaged immediately in an IVIS LUMINA II system, using the
- 214 sequence settings described above. Luminescence data were extracted using Living Image Software,
- 215 using the standard 12X8 grid ROI setting.

216 Haematological and iron parameters

- 217 Peripheral venous blood from participants was collected into lithium heparin tubes. Some blood was
- subject to haematological analysis for a full blood count using an ABX Pentra 60 system and the
- remainder was used to extract plasma by spinning at 2500g for 10min at 4C. Plasma samples were
- 220 immediately stored at -80C for further analysis.

- Haemoglobin in mice was recorded from fresh blood using the HemoCue Hb 201+ system. To extract
- serum, blood was allowed to clot at room temperature for 2 hours, before spinning at 4000g for 10
- 223 min. Serum was stored at -80C for further analysis.
- 224 Iron, serum ferritin, transferrin levels were determined in human plasma and mouse serum using the
- ABX-Pentra C400 system (Horiba). Transferrin saturation was calculated using iron and transferrin
- 226 concentrations. NTBI measurements were carried out by Sanquin Diagnostic Services (Amesterdam)
- as described previously³⁸. It was not possible to obtain data on serum iron and NTBI from some
- 228 animals due to the amount of serum collected not meeting the minimum volume requirements for
- the respective assays.
- 230 MDA levels were measured in plasma or serum using Lipid Peroxidation kit Abcam (ab233471)
- according to the manufacturer's instructions.

232 Statistical analysis

- Data in figures are shown as mean ±standard error of the mean ±S.E.M. In-text values are reported
 as mean ±STDEV.
- 235 Normality and equal variance were tested using the Shapiro-Wilk test and Levene test respectively.
- 236 Pairwise comparisons were drawn using 2-tailed, unpaired t test (for sample size n≥5), or Mann-
- 237 Whitney test (for sample size<5). Multiple group comparisons were drawn using a 1-way or 2-way
- 238 ANOVA followed by Dunnett's post hoc test. Longitudinal repeated measure data in patients were
- analysed using mixed effects analysis to account for missing data, with Dunnett's multiple
- 240 comparison test. P value of less than 0.05 was considered statistically significant. Analysis was
- 241 carried out using GraphPad PRISM.10

242 **<u>RESULTS</u>**

243 Ferric carboxymaltose treatment in patients results in rapid and sustained rise in myocardial iron

- 244 Between October 18th 2022 and July 31st 2023, 54 patients were screened for eligibility, of whom 13
- were recruited, and 12 completed the study (Figure 1). Patient demographics and baseline
- characteristics are shown in Table 1.

247 Table 1- Patient demographics and baseline characteristics (n=12)

Characteristic	Value			
Age (years), median (IQR), [Range]	44 (12) [27-69]			
Sex, n (%)				
Female / Male	11 (91)/ 1 (9)			
Weight (kg), mean (SD)	71.2 (13.7)			
BMI (kg/m²), median (IQR)	27.2 (5.7)			
Ethnicity, n (%)				
White 6 (50)				
South Asian	4 (33)			
Black	1 (17)			
Mixed	0 (0)			
Other	1 (17)			
Reason for referral n, (%)				
Heavy menstrual bleeding	8 (66.8%)			
Abnormal uterine bleeding (e.g. fibroids)	1 (8.3%)			
Rectal bleeding	1 (8.3%)			

medRxiv preprint doi: https://doi.org/10.1101/2024.01.18.24301496; this version posted March 11, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-ND 4.0 International license .

IDA of unclear aetiology	2 (16.6%)
Previous IV iron infusions, n (%)	
None	9 (75)
One prior infusion	3 (25)
Relevant comorbidities, n (%)	
Ischaemic heart disease	0 (0)
Chronic respiratory disease (asthma, COPD)	0 (0)
Laboratory iron parameters at referral (Normal range), median	
(IQR)	
Haemoglobin (120- 170), g/l	106 (12)
Ferritin (10 – 300), mcg/l	7.4 (10.1)
Tsat (16 – 50), %	7 (3)

248 BMI, Body Mass Index; COPD, Chronic Obstructive Pulmonary Disease; IDA, Iron deficiency anaemia;

249 IQR, Interquartile range; IV, intravenous; SD, Standard deviation; Tsat, Transferrin saturation

250 To assess the short and long-term impact of FCM on myocardial iron, participants were scanned

immediately prior to infusion (0h), then three hours (3h), 14 days and 42 days post infusion (Figure

252 2A). At 3h post infusion, myocardial T1 dropped in 11/12 participants, with a mean change (Δ T1) of -

253 35.35±26.88ms(p=0.0008). At 14 days and 42days post infusion, myocardial T1 was still lower than

254 Oh values, with a change of -26.76±32.93ms (p=0.0255) and -28.45±20.33ms (p=0.008) respectively.

255 Importantly, Δ T1 values at days 14 and 42 were not significantly different from those at 3h post

infusion (p=0.709 and 0.775 respectively) (figure 2B). Thus, a single standard dose of FCM in patients

with iron deficiency raises myocardial iron rapidly and maximally within 3 hours, and this rise is

sustained for at least 42 days post infusion.

259 To understand the pathways underlying the rise in myocardial iron, we also assessed changes in

spleen and liver iron, where reticuloendothelial macrophages reside. Splenic T1 dropped in all

261 participants at 3hrs post infusion, with a mean drop (ΔT1) of -39.7±36.2ms (p<0.0001). However

maximal drop of -193.9±30.59ms was only seen at 14 days (p<0.0001). By 42 days post infusion, the

263 mean drop ΔT1 was -137±33.68ms (p<0.0001). Between days 14 and 42, there was a statistically

significant recovery in Δ T1 values (p=0.0004) (Figure 2C). Thus, after a single standard dose of FCM in

patients with iron deficiency, spleen iron begins to rise within 3 hours, but rises maximally at 14

days, and is declining by 42 days.

267 Next, we assessed T1 changes in the liver. At 3h post infusion, liver T1 dropped in 11/12 participants.

268 The mean ΔT1 was -23±19.9ms (p=0.0168). By 14 days and 42days post infusion, liver ΔT1values had

269 diverged markedly amongst participants, and were no longer statistically significantly different from

270 Oh values (p=0.093 and 0.829 respectively) (Figure 2D).

271 In terms of circulating iron, plasma iron concentration rose sharply in all participants from a mean

- concentration of 14.05±2.52uM at 0h to 246.64±10.60uM at 3 hours (p<0.0001), then declined to
- 273 22.01±1.14uM at 14 days and to 22.23±2.31uM at 42 days such that plasma iron levels at these
- timepoints were no longer significantly higher than what they were at 0h (p=0.78 and 0.722
- 275 respectively) (Figure 2E).

Transferrin saturation (Tsat) rose sharply in all participants from 16.74±3.65% at 0h to full saturation at 3 hours (p<0.0001), then declined to 36.68±3.78% at 14 days and 44.82±4.12% at 42 days, though it remained significantly higher than it was at 0h (p=0.0034 and p<0.0001 respectively) (Figure 2F).

- 279 Plasma NTBI levels rose sharply in all participants from being below detection (assay LLOD is
- 280 0.607uM) at 0h to 14.16±1.87uM at 3 hours post FCM infusion(p<0.0001), then declined at day 14 to

- 281 below the LLOD in all participants but one, such that the mean concentration at this timepoint was
- 282 0.102±0.073µM at 14 days (p=0.999 compared to 0h). At 42 days post infusion, NTBI levels were
- below the detection limit for all participants (>0.999 compared to 0h) (Figure 2G).

284 The presence of labile iron entities such as NTBI generates peroxides which in turn react with

- susceptible molecules, including certain lipids. Plasma malondialdehyde (MDA), a biomarker of lipid
- peroxidation rose in all participants from a mean of 1.908±0.0185uM at 0h to 2.007±0.0180uM at 3
- 287 hours (p<0.0001). They declined to 1.886±0.005uM at day 14 such that they were no longer different
- from 0h (p=0.7816), and then declined further to 1.858±0.010uM at day 42 (p=0.0473 relative to 0h)
- 289 (Figure 2H)
- 290 In terms of plasma ferritin, mean levels were 12.77±6.27ug/mL at 0h and were not significantly
- different at 3hours post infusion (8.925±5.08ug/mL, p=0.9983). However, they rose to 344±41.59
- ug/mL at 14 days (p<0.0001 relative 0h) and 65.8±18.99 ug/mL at 42 days (p=0.0041 relative to 0h)
- 293 The decline in ferritin levels from day 14 to day 42 was significant (p=0.0029) (Figure 2I).
- 294 We also assessed the levels of the iron homeostatic hormone hepcidin, which were at
- 295 2.12±ng1.139ng/mL at 0h, remaining unchanged at 3h (3.16±1.55ng/ml, p=0.9923) but rising
- significantly to 15.9±4.27ng/mL at 14 days (p=0.0301) and further still to 23.93±5.05ng/mL at 42
- 297 days (p=0.0004) (Figure 2J).
- Haematological parameters, including haemoglobin, haematocrit and mean corpuscular volume
 were all significantly improved at days 14 and 42 compared to 0h (Figure 2k-m).
- 300 These data demonstrate that following infusion of a standard dose of FCM in iron-deficient patients,
- 301 the myocardium takes up iron quickly, within 3 hours, coinciding with maximal rises in serum iron
- availability, both transferrin and non-transferrin bound. The iron taken up within the first 3 hours is
- retained in the myocardium for at least 42 days, despite declining serum iron availability. This is in
- 304 contrast to the spleen, where iron uptake is maximal at 14 days, subsequently declining by 42days,.
- Additionally, changes in plasma ferritin levels followed the pattern of changes in splenic iron.

Ferric carboxymaltose treatment in mice results in rapid and sustained rise in myocardial labile iron pool (LIP).

- 308 Having observed an increase in myocardial iron following FCM infusion in patients, we sought to
- determine how this iron is handled in the myocardium. To that effect, we used iron-caged luciferin
- 310 (ICL-1), which is only converted into the substrate of the cytoplasmic enzyme luciferase in the
- 311 presence of cytoplasmic labile iron. This approach was used to quantitatively assess the impact on
- 312 myocardial LIP of a single intravenous infusion of FCM (15mg/kg iron) into iron-replete or iron-
- deficient mice 1 hour or 42 days after infusion (Figure 3A). The iron status of mice was confirmed
- 314 (supplemental Figure 2A, B).
- 315 In FCM-treated iron-deficient mice, myocardial LIP was raised both 1 hour after infusion (p=0.028 vs
- saline) and 42 days after infusion (p=0.013 vs saline) (Figure 3B). In FCM-treated iron-replete mice,
- 317 myocardial LIP was raised 1 hour post infusion (p=0.035 vs saline) and there was also a trend for the
- increase to be sustained 42 days after infusion (p=0.06 saline vs FCM) (Figure 3B). Of note,
- 319 myocardial LIP was lower in iron-deficient mice than in iron-replete mice (p=0.0047) (Supplemental
- 320 figure 2C)
- 321 As with patients, we sought to understand the pathways underpinning the rise in myocardial iron.
- 322 FCM infusion into iron-deficient mice raised spleen iron within 1 hour (p=0.02 relative to saline),
- 323 through the rise was much more pronounced 42 days post infusion (p=0.004 relative to saline). In

- iron-replete mice, FCM infusion did not raise spleen iron after 1 hour, but did so after 42 days
- 325 (p=0.015 relative to saline) (Figure 3C). Changes in liver iron followed a similar trend as changes in
- 326 spleen iron (Figure 3D). In terms of circulating iron availability, serum iron levels were raised by FCM
- 327 infusion in comparison to saline in iron-deficient mice 1 hour after infusion (p<0.0001 relative to
- 328 saline), and were still raised 42 days post infusion (p=0.0002 relative to saline). In iron-replete mice,
- 329 serum iron levels were raised 1 hour after FCM infusion (p<0.0001 relative to saline) but not
- significantly so 42 days after infusion (p=0.392 relative to saline) (Figure 3E). Changes in transferrin
- saturation (Tsat) reflected changes in serum iron levels, with full or near full saturation seen 1 hour
- after FCM infusion (Figure 3F). Consistent with this, NTBI was below the detection limit in saline-
- treated mice, but rose markedly 1 hour after FCM infusion in both iron-deficient mice (p=0.0003
 relative to saline) and iron-replete mice (p=0.019 relative to saline). There was some residual NTBI
- 42 days post FCM infusion in iron-deficient mice (p=0.016 relative to saline). (Figure 3G).
- FCM did not have an acute effect on serum ferritin in either iron-deficient of iron-replete mice, but raised serum ferritin in iron-deficient mice after 42 days (p=0.0155 relative to saline) (supplemental
- 338 figure 2D).
- 339 These preclinical data confirm the previous clinical observation that FCM results in a rapid and
- 340 sustained increase in myocardial iron and further demonstrate that the iron taken up by the
- 341 myocardium is in labile (reactive) form, and remains so for at least 42 days post treatment.

342 Exposure to ferric carboxymaltose raises cellular LIP in cardiac myocytes via NTBI transporters

- 343 The rapid rise in myocardial iron following FCM infusion indicates direct myocardial uptake of iron
- 344 from the circulation through a pathway that bypasses reticuloendothelial macrophages. To ascertain
- direct uptake and determine its route(s), we used the rat cardiac myocyte cell line H2C9, transfected
- 346 via lentivirus, to express the luciferase transgene (Supplemental Figure 3). FCM was added to the
- 347 growth media at a concentration of 0.25mg iron/mL to reflect a standard patient dose. To eliminate
- 348 any confounding effects of iron from the growth media additive fetal bovine serum (FBS), cardiac
- 349 myocytes were switched to FBS-free growth media two hours before and throughout exposure to
- 350 FCM or saline (Figure 4A).
- 351 Compared to saline treatment, FCM in growth media raised cellular LIP in cardiac myocytes at 0.5h
- 352 (p=0.039 relative to saline) and 2h (p=0.0204 relative to saline) (Figure 4B). Given that this rise
- 353 occurred in the absence of FBS (the source of transferrin in growth media), we postulated that it was
- 354 the result of NTBI uptake. To test this hypothesis, we determined the impact of efonidipine, an
- 355 inhibitor of L-type and T-type calcium channels (LTCC and TTCC), and Ebselen, an inhibitor of the
- 356 ferrous iron transporter divalent metal transporter DMT1. We found that Ebselen reduced
- 357 (p=0.0372 compared to FCM alone) and efonidipine completely prevented (p<0.0001 compared to
- 358 FCM alone) the rise in cardiac myocyte LIP (Figure 4C).
- Consistent with this, NTBI was present in the supernatants of FCM-treated cells, being below thedetection limit in the supernatants of saline-treated cells (p=0.0014) (Figure 4D).
- 361 These data confirm that FCM treatment raises LIP in cardiac myocytes and further demonstrate this
- rise is due to the uptake of extracellular NTBI derived from FCM.
- 363

364 Discussion

365 While IV iron therapies have been suggested to raise the iron content of certain tissues, including

- the heart³⁹, the mechanisms underlying this rise, and the ultimate fate of the iron that is taken up
- 367 remained unknown. The present study addresses these unknowns in the context of the heart,
- 368 through longitudinal assessment of changes in myocardial iron relative to changes in splenic, liver
- 369 and circulating iron, and specific tracing, of cellular labile iron, the immediate product of iron uptake.

370 The key and novel finding of the present study is that the rise in myocardial iron following a standard 371 dose of intravenous iron with FCM results from rapid and direct uptake of FCM-derived NTBI in the 372 circulation. Indeed, in iron-deficient patients and in mice, myocardial iron content peaked within 373 hours of FCM infusion, a timeframe that is too rapid to be attributed to the canonical pathway of 374 FCM degradation by reticuloendothelial macrophages. Indeed, splenic iron in patients (closely 375 followed by plasma ferritin levels), only peaked at 14 days post infusion, and began to decline by 42 376 days post infusion, consistent with the initial uptake of FCM and subsequent release of iron into the 377 circulation. Acute rises in circulating iron levels, including the appearance of NTBI in patients and in 378 mice, and the presence of NTBI in the supernatants of FCM-treated cells demonstrate that ferric 379 carboxymaltose complex releases some of its iron directly into the circulation and in quantities that 380 are sufficient to alter the iron content of the myocardium. A previous pharmacokinetic study of intravenous iron formulations in healthy volunteers also detected acute rises in NTBI and estimated 381 382 that 10-40% of the iron contained within FCM is released rapidly and directly into the circulation as 383 NTBI²⁴. In cultured cardiac myocytes, exposure to clinically relevant dose of FCM raised intracellular iron content in the absence of any macrophages, and in a manner that was primarily dependent on 384 385 LTCC and or TTCC, and to a lesser extent DMT1, recognised NTBI transporters that are abundantly 386 expressed in the heart, and known to be responsible for iron-overload cardiomyopathy in thalassaemia and hemochromatosis ²⁵⁻²⁷. While DMT1 is regulated by IRPs according to cellular iron 387 388 needs, LTCCs and TTCCs are not regulated in this manner, continuing to take up iron into cells 389 despite excess intracellular iron levels.

390 The second key and novel finding of the present study is that the iron taken up into the myocardium 391 following FCM treatment remains in labile form for weeks. Specialised organs of iron handling, such 392 as the spleen and liver, are characterised by high iron storage capacity and rapid iron turnover owing to abundant levels of ferritin and ferroportin respectively^{28,29,40}. That iron taken up into the 393 394 myocardium remains labile 42 days later, is consistent with the fact that the myocardium is not a specialised organ of iron handling, and has relatively limited capacity for iron storage and 395 396 turnover^{28,29}. Intriguingly, in the spleen and liver, other relaxation parameters T2 and T2* echoed 397 changes in T1, dropping significantly following FCM infusion, with maximal drops at 14 days post 398 infusion (supplemental figure 4A-D). In contrast, changes in myocardial T2 and T2* did not echo 399 changes in myocardial T1 and diverged greatly between participants, with myocardial Δ T2 only 400 trending towards a significant drop at 42 days post infusion (p=0.086 compared to 0h) (supplemental figure 4E,F). The lack of concordance between myocardial relaxation parameters T1, T2 and T2* is a 401 well-recognised phenomenon ⁴¹⁻⁴³. T1 has been shown to have higher sensitivity than T2* for 402 403 detecting milder myocardial iron loading in thalassaemia patients, and may be better at resolving small increases following IV iron therapy^{41,42}. Changes in relaxation parameters reflect microscopic 404 405 inhomogeneity in the magnetic field, created by the distribution of iron inside cells. Unbound labile 406 iron has a diffuse cytoplasmic distribution, in contrast to stored iron, where up to 4500 atoms of iron are clustered inside the 80 Å diameter cavity of the ferritin molecule⁴³. Thus, it is likely that labile 407 408 iron affects the magnetic field, and consequently relaxation parameters, differently from the stored 409 iron. Our findings are consistent with the idea that T1 better reflects labile iron entities, while T2 and 410 T2* better reflect stored iron entities.

- 411 The findings of the current study have important clinical implications. The lack of iron clearance from
- 412 the myocardium over the period of 42 days highlights the potential for cumulative build up with
- 413 repeated doses. Based on the observed mean drop in myocardial T1 of -28.45ms after a single IV
- 414 iron dose, calculations estimate that 6 doses would cumulatively lower myocardial T1 to below
- 850ms, the cut-off shown to predict iron overload cardiomyopathy ⁴⁴ (supplemental table 1). This 415
- raises pertinent questions about the safety of long-term IV iron therapy, increasingly being adopted 416
- 417 in some patients, e.g. malabsorptive disorders, women with heavy uterine bleeding, chronic
- 418 disorders^{45,46}. Trials of long-term IV iron therapy in heart failure patients (where up to 9 doses were
- 419 administered) have not reported an increased risk of adverse effects^{1, 47-49}. However, myocardial iron
- 420 content was not monitored in these studies, and any manifestation of cardiac iron toxicity could 421 have been masked by the clinical signs of pre-existing heart failure. In these settings, minimum and
- 422 maximum ferritin cut offs are often used to inform the need for further IV iron doses, and to
- 423 safeguard against the risk of parenchymal iron overload respectively. However, our findings that
- 424 myocardial iron uptake following IV iron therapy is independent of reticuloendothelial macrophages
- 425 indicate that are also uncoupled from changes in plasma ferritin levels. Hence ferritin cut-offs may
- 426 not be appropriate to safeguard against the risk of myocardial iron overload in patients on long term
- 427 IV iron therapy, and MR based monitoring of myocardial iron should be considered instead.
- 428 Additionally, in settings where myocardial iron repletion maybe desirable, the benefits sustained by
- 429 patients would be independent of changes in plasma ferritin levels¹.

Study limitations 430

- The clinical findings of the present study are derived from a relatively small number of participants. 431
- 432 Most of these were women with iron deficiency due to heavy menstrual bleeding, and it remains to
- 433 be determined if the study's findings can be generalised to patient groups with different aetiologies
- of iron deficiency. Though not specific to this study, the use of MR relaxometry to estimate tissue 434
- 435 iron content has a its limitations. For instance, relaxometry results depend on the choice of
- 436 sequence and inferences on tissue iron content hinge on a gross simplification that the relaxivity
- 437 coefficients for all/any iron species in blood and tissue are similar across all study visits⁵⁰.
- 438 The pre-clinical findings of the present study rely on luminescence-based imaging of labile iron, with 439 the main limitation that imaging is conducted on isolated hearts, to safeguard against interferences 440 from surrounding tissues, including the epidermis and fur. Excision of the heart prior to LIP imaging
- 441 has the potential to impact on luciferase enzyme activity and total luminescence signal, though this
- 442 risk would have been present in all experimental groups.

443 Acknowledgements

- 444 SL-L conceived project, secured funds, analysed data and wrote manuscript. PP and MD recruited 445 patients. AS performed study procedures in participants. VF and SP designed MR imaging protocol 446 and analysed MR data. MVA, KS, YL, CB, PB, PH, DS, HM performed experiments. All reviewed and 447 commented on manuscript.
- 448 We are grateful to OCMR radiographers Dilliram Adhikari, Neil Fox, Joana Leal Pelado and Rebecca 449 Mills for running MRI scans.
- 450 We are grateful to all the participants (and their families) who took part, without whom this study 451 would not have been possible.
- 452 Funding

- 453 S L-L is funded by the Medical Research Council (MR/ V009567/1/) and the British Heart Foundation
- 454 Centre for Research Excellence HSR00031 and RE/18/3/34214. YL is funded by the British Heart
- 455 Foundation Centre for Research RE/18/3/34214. CB is funded by the Wellcome Trust. AS is currently
- 456 supported by a National Institute for Health and Care Research Academic Clinical Lectureship award.

457 Disclosure of interest

- 458 S.L-L reports receipt of previous research funding from Vifor Pharma, personal honoraria on a
- 459 lecture from Pharmacosmos and consultancy fees from Disc Medicine and ScholarRock. AS is an
- 460 Editor of Anaesthesia.

461 Data availability statement

462 Research data will be made available upon reasonable request.

463 <u>References</u>

- 464
- Lakhal-Littleton, S, Cleland JG. Iron deficiency and supplementation in heart failure. Nature
 Reviews Cardiology. In press
- von Haehling S, Gremmler U, Krumm M, Mibach F, Schön N, Taggeselle J, et al. Prevalence
 and clinical impact of iron deficiency and anaemia among outpatients with chronic heart
 failure: The PrEP Registry. Clin Res Cardiol. 2017 Jun;106(6):436–43. doi:10.1007/s00392 016-1073-y
- Jankowska EA, Rozentryt P, Witkowska A, Nowak J, Hartmann O, Ponikowska B, et al. Iron
 deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J. 2010
 Aug;31(15):1872–80. doi:10.1093/eurheartj/ehq158
- Ghio A, Hilborn ED. Indices of iron homeostasis correlate with airway obstruction in an
 NHANES III cohort. Int J Chron Obstruct Pulmon Dis. 2017 Jul 18;12:2075–84.
 doi:10.2147/copd.s138457
- 5. Silverberg DS, Mor R, Tia Weu M, Schwartz D, Schwartz IF, Chernin G. Anemia and iron
 deficiency in COPD patients: prevalence and the effects of correction of the anemia with
 erythropoiesis stimulating agents and intravenous iron. BMC Pulm Med. 2014 Feb 24;14(1).
 doi:10.1186/1471-2466-14-24
- 481
 6. Eisenga MF, Nolte IM, van der Meer P, Bakker SJL, Gaillard CAJM. Association of different
 482 iron deficiency cutoffs with adverse outcomes in chronic kidney disease. BMC Nephrol. 2018
 483 Sep 12;19(1). doi:10.1186/s12882-018-1021-3
- 484
 484
 485
 485
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
- 487 8. Crawford J, Cella D, Cleeland CS, Cremieux P, Demetri GD, Sarokhan BJ, et al. Relationship
 488 between changes in hemoglobin level and quality of life during chemotherapy in anemic
 489 cancer patients receiving epoetin alfa therapy. Cancer. 2002 Aug 15;95(4):888–95.
 490 doi:10.1002/cncr.10763
- 491 9. Gasche C, Lomer MCE, Cavill I, Weiss G. Iron, anaemia, and inflammatory bowel diseases.
 492 Gut. 2004 Aug;53(8):1190–7. doi:10.1136/gut.2003.035758
- 493 10. Dignass AU, Gasche C, Bettenworth D, Birgegård G, Danese S, Gisbert JP, et al. European
 494 Consensus on the Diagnosis and Management of Iron Deficiency and Anaemia in
 495 Inflammatory Bowel Diseases. J Crohns Colitis. 2015 Mar;9(3):211–22. doi:10.1093/ecco496 jcc/jju009

497	11.	Vidal F, Gillibert A, Quillard M, Fardellone P, Vittecoq O, Lequerré T. Does iron deficiency
498		contribute to fatigue in patients with rheumatoid arthritis without anemia? Joint Bone
499		Spine. 2020 Jan;87(1):89. doi:10.1016/j.jbspin.2019.06.004
500	12.	Fowler AJ, Ahmad T, Phull MK, Allard S, Gillies MA, Pearse RM. Meta-analysis of the
501		association between preoperative anaemia and mortality after surgery. Br J Surg. 2015
502		Oct;102(11):1314-24. doi: 10.1002/bjs.9861.
503	13.	Low MSY, Speedy J, Styles CE, De-Regil LM, Pasricha S-R. Daily Iron Supplementation for
504		improving anaemia, iron status and health in menstruating women. Cochrane Database Syst
505		Rev. 2016 Apr 18;2016(4). doi:10.1002/14651858.cd009747.pub2
506	14.	American Regent, Inc. Venofer Prescribing Information. Shirley, New York: American Regent,
507		Inc.; 2022. Available from: https://www.venofer.com/pdfs/venofer-prescribing-
508		information.pdf
509	15.	Sanofi Aventis US. Ferrlecit Prescribing Information. Silver Spring, Maryland: Food and Drug
510		Administration; 2022. Available from:
511		https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020955s020lbl.pdf
512	16.	Pharmacosmos Therapeutics Inc. MONOFERRIC Prescribing Information. Silver Spring,
513		Maryland: Food and Drug Administration; 2022. Available from:
514		https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208171Orig1s002lbl.pdf
515	17.	American Regent, Inc. Injectafer Prescribing Information. Silver Spring, Maryland: Food and
516		Drug Administration; 2023. Available from:
517		https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203565s024lbl.pdf
518	18.	Funk F. Flühmann B. Barton AE. Criticality of Surface Characteristics of Intravenous Iron–
519		Carbohydrate Nanoparticle Complexes: Implications for Pharmacokinetics and
520		Pharmacodynamics Int I Mol Sci. 2022 Feb 15:23(4):2140. doi:10.3390/ijms23042140
520		
520	19.	Alphandéry E. Iron oxide nanoparticles for therapeutic applications. Drug Discov Today. 2020
521 522	19.	Alphandéry E. Iron oxide nanoparticles for therapeutic applications. Drug Discov Today. 2020 Jan;25(1):141–9. doi:10.1016/j.drudis.2019.09.020
521 522 523	19. 20.	Alphandéry E. Iron oxide nanoparticles for therapeutic applications. Drug Discov Today. 2020 Jan;25(1):141–9. doi:10.1016/j.drudis.2019.09.020 Arami H, Khandhar A, Liggitt D, Krishnan KM. In vivo delivery, pharmacokinetics,
520 521 522 523 524	19. 20.	Alphandéry E. Iron oxide nanoparticles for therapeutic applications. Drug Discov Today. 2020 Jan;25(1):141–9. doi:10.1016/j.drudis.2019.09.020 Arami H, Khandhar A, Liggitt D, Krishnan KM. In vivo delivery, pharmacokinetics, biodistribution and toxicity of iron oxide nanoparticles. Chem Soc Rev. 2015 Dec
520 521 522 523 524 525	19. 20.	Alphandéry E. Iron oxide nanoparticles for therapeutic applications. Drug Discov Today. 2020 Jan;25(1):141–9. doi:10.1016/j.drudis.2019.09.020 Arami H, Khandhar A, Liggitt D, Krishnan KM. In vivo delivery, pharmacokinetics, biodistribution and toxicity of iron oxide nanoparticles. Chem Soc Rev. 2015 Dec 7;44(23):8576–607. doi:10.1039/c5cs00541h
521 522 523 524 525 526	19. 20. 21.	Alphandéry E. Iron oxide nanoparticles for therapeutic applications. Drug Discov Today. 2020 Jan;25(1):141–9. doi:10.1016/j.drudis.2019.09.020 Arami H, Khandhar A, Liggitt D, Krishnan KM. In vivo delivery, pharmacokinetics, biodistribution and toxicity of iron oxide nanoparticles. Chem Soc Rev. 2015 Dec 7;44(23):8576–607. doi:10.1039/c5cs00541h Rouault T, Klausner R. Regulation of iron metabolism in eukaryotes. Current Topics in
521 522 523 524 525 526 527	19. 20. 21.	Alphandéry E. Iron oxide nanoparticles for therapeutic applications. Drug Discov Today. 2020 Jan;25(1):141–9. doi:10.1016/j.drudis.2019.09.020 Arami H, Khandhar A, Liggitt D, Krishnan KM. In vivo delivery, pharmacokinetics, biodistribution and toxicity of iron oxide nanoparticles. Chem Soc Rev. 2015 Dec 7;44(23):8576–607. doi:10.1039/c5cs00541h Rouault T, Klausner R. Regulation of iron metabolism in eukaryotes. Current Topics in Cellular Regulation. 1997 Jan 1;35:1–19. doi:10.1016/s0070-2137(97)80001-5
521 522 523 524 525 526 527 528	19. 20. 21. 22.	Alphandéry E. Iron oxide nanoparticles for therapeutic applications. Drug Discov Today. 2020 Jan;25(1):141–9. doi:10.1016/j.drudis.2019.09.020 Arami H, Khandhar A, Liggitt D, Krishnan KM. In vivo delivery, pharmacokinetics, biodistribution and toxicity of iron oxide nanoparticles. Chem Soc Rev. 2015 Dec 7;44(23):8576–607. doi:10.1039/c5cs00541h Rouault T, Klausner R. Regulation of iron metabolism in eukaryotes. Current Topics in Cellular Regulation. 1997 Jan 1;35:1–19. doi:10.1016/s0070-2137(97)80001-5 Cohen LA, Gutierrez L, Weiss A, Leichtmann-Bardoogo Y, Zhang D, Crooks DR, et al. Serum
521 522 523 524 525 526 527 528 529	19. 20. 21. 22.	Alphandéry E. Iron oxide nanoparticles for therapeutic applications. Drug Discov Today. 2020 Jan;25(1):141–9. doi:10.1016/j.drudis.2019.09.020 Arami H, Khandhar A, Liggitt D, Krishnan KM. In vivo delivery, pharmacokinetics, biodistribution and toxicity of iron oxide nanoparticles. Chem Soc Rev. 2015 Dec 7;44(23):8576–607. doi:10.1039/c5cs00541h Rouault T, Klausner R. Regulation of iron metabolism in eukaryotes. Current Topics in Cellular Regulation. 1997 Jan 1;35:1–19. doi:10.1016/s0070-2137(97)80001-5 Cohen LA, Gutierrez L, Weiss A, Leichtmann-Bardoogo Y, Zhang D, Crooks DR, et al. Serum ferritin is derived primarily from macrophages through a nonclassical secretory pathway.
521 522 523 524 525 526 527 528 529 530	19. 20. 21. 22.	Alphandéry E. Iron oxide nanoparticles for therapeutic applications. Drug Discov Today. 2020 Jan;25(1):141–9. doi:10.1016/j.drudis.2019.09.020 Arami H, Khandhar A, Liggitt D, Krishnan KM. In vivo delivery, pharmacokinetics, biodistribution and toxicity of iron oxide nanoparticles. Chem Soc Rev. 2015 Dec 7;44(23):8576–607. doi:10.1039/c5cs00541h Rouault T, Klausner R. Regulation of iron metabolism in eukaryotes. Current Topics in Cellular Regulation. 1997 Jan 1;35:1–19. doi:10.1016/s0070-2137(97)80001-5 Cohen LA, Gutierrez L, Weiss A, Leichtmann-Bardoogo Y, Zhang D, Crooks DR, et al. Serum ferritin is derived primarily from macrophages through a nonclassical secretory pathway. Blood. 2010 Sep 2;116(9):1574–84. doi:10.1182/blood-2009-11-253815
520 521 522 523 524 525 526 527 528 529 530 531	 19. 20. 21. 22. 23. 	Alphandéry E. Iron oxide nanoparticles for therapeutic applications. Drug Discov Today. 2020 Jan;25(1):141–9. doi:10.1016/j.drudis.2019.09.020 Arami H, Khandhar A, Liggitt D, Krishnan KM. In vivo delivery, pharmacokinetics, biodistribution and toxicity of iron oxide nanoparticles. Chem Soc Rev. 2015 Dec 7;44(23):8576–607. doi:10.1039/c5cs00541h Rouault T, Klausner R. Regulation of iron metabolism in eukaryotes. Current Topics in Cellular Regulation. 1997 Jan 1;35:1–19. doi:10.1016/s0070-2137(97)80001-5 Cohen LA, Gutierrez L, Weiss A, Leichtmann-Bardoogo Y, Zhang D, Crooks DR, et al. Serum ferritin is derived primarily from macrophages through a nonclassical secretory pathway. Blood. 2010 Sep 2;116(9):1574–84. doi:10.1182/blood-2009-11-253815 Ferring-Appel D, Hentze MW, Galy B. Cell-autonomous and systemic context-dependent
521 522 523 524 525 526 527 528 529 530 531 532	 19. 20. 21. 22. 23. 	Alphandéry E. Iron oxide nanoparticles for therapeutic applications. Drug Discov Today. 2020 Jan;25(1):141–9. doi:10.1016/j.drudis.2019.09.020 Arami H, Khandhar A, Liggitt D, Krishnan KM. In vivo delivery, pharmacokinetics, biodistribution and toxicity of iron oxide nanoparticles. Chem Soc Rev. 2015 Dec 7;44(23):8576–607. doi:10.1039/c5cs00541h Rouault T, Klausner R. Regulation of iron metabolism in eukaryotes. Current Topics in Cellular Regulation. 1997 Jan 1;35:1–19. doi:10.1016/s0070-2137(97)80001-5 Cohen LA, Gutierrez L, Weiss A, Leichtmann-Bardoogo Y, Zhang D, Crooks DR, et al. Serum ferritin is derived primarily from macrophages through a nonclassical secretory pathway. Blood. 2010 Sep 2;116(9):1574–84. doi:10.1182/blood-2009-11-253815 Ferring-Appel D, Hentze MW, Galy B. Cell-autonomous and systemic context-dependent functions of iron regulatory protein 2 in mammalian iron metabolism. Blood. 2009 Jan
520 521 522 523 524 525 526 527 528 529 530 531 532 532 533	 19. 20. 21. 22. 23. 	Alphandéry E. Iron oxide nanoparticles for therapeutic applications. Drug Discov Today. 2020 Jan;25(1):141–9. doi:10.1016/j.drudis.2019.09.020 Arami H, Khandhar A, Liggitt D, Krishnan KM. In vivo delivery, pharmacokinetics, biodistribution and toxicity of iron oxide nanoparticles. Chem Soc Rev. 2015 Dec 7;44(23):8576–607. doi:10.1039/c5cs00541h Rouault T, Klausner R. Regulation of iron metabolism in eukaryotes. Current Topics in Cellular Regulation. 1997 Jan 1;35:1–19. doi:10.1016/s0070-2137(97)80001-5 Cohen LA, Gutierrez L, Weiss A, Leichtmann-Bardoogo Y, Zhang D, Crooks DR, et al. Serum ferritin is derived primarily from macrophages through a nonclassical secretory pathway. Blood. 2010 Sep 2;116(9):1574–84. doi:10.1182/blood-2009-11-253815 Ferring-Appel D, Hentze MW, Galy B. Cell-autonomous and systemic context-dependent functions of iron regulatory protein 2 in mammalian iron metabolism. Blood. 2009 Jan 15;113(3):679–87. doi:10.1182/blood-2008-05-155093
520 521 522 523 524 525 526 527 528 529 530 531 532 533 534	 19. 20. 21. 22. 23. 24. 	Alphandéry E. Iron oxide nanoparticles for therapeutic applications. Drug Discov Today. 2020 Jan;25(1):141–9. doi:10.1016/j.drudis.2019.09.020 Arami H, Khandhar A, Liggitt D, Krishnan KM. In vivo delivery, pharmacokinetics, biodistribution and toxicity of iron oxide nanoparticles. Chem Soc Rev. 2015 Dec 7;44(23):8576–607. doi:10.1039/c5cs00541h Rouault T, Klausner R. Regulation of iron metabolism in eukaryotes. Current Topics in Cellular Regulation. 1997 Jan 1;35:1–19. doi:10.1016/s0070-2137(97)80001-5 Cohen LA, Gutierrez L, Weiss A, Leichtmann-Bardoogo Y, Zhang D, Crooks DR, et al. Serum ferritin is derived primarily from macrophages through a nonclassical secretory pathway. Blood. 2010 Sep 2;116(9):1574–84. doi:10.1182/blood-2009-11-253815 Ferring-Appel D, Hentze MW, Galy B. Cell-autonomous and systemic context-dependent functions of iron regulatory protein 2 in mammalian iron metabolism. Blood. 2009 Jan 15;113(3):679–87. doi:10.1182/blood-2008-05-155093 Garbowski MW, Bansal S, Porter JB, Mori C, Burckhardt S, Hider RC. Intravenous iron
520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 535	 19. 20. 21. 22. 23. 24. 	Alphandéry E. Iron oxide nanoparticles for therapeutic applications. Drug Discov Today. 2020 Jan;25(1):141–9. doi:10.1016/j.drudis.2019.09.020 Arami H, Khandhar A, Liggitt D, Krishnan KM. In vivo delivery, pharmacokinetics, biodistribution and toxicity of iron oxide nanoparticles. Chem Soc Rev. 2015 Dec 7;44(23):8576–607. doi:10.1039/c5cs00541h Rouault T, Klausner R. Regulation of iron metabolism in eukaryotes. Current Topics in Cellular Regulation. 1997 Jan 1;35:1–19. doi:10.1016/s0070-2137(97)80001-5 Cohen LA, Gutierrez L, Weiss A, Leichtmann-Bardoogo Y, Zhang D, Crooks DR, et al. Serum ferritin is derived primarily from macrophages through a nonclassical secretory pathway. Blood. 2010 Sep 2;116(9):1574–84. doi:10.1182/blood-2009-11-253815 Ferring-Appel D, Hentze MW, Galy B. Cell-autonomous and systemic context-dependent functions of iron regulatory protein 2 in mammalian iron metabolism. Blood. 2009 Jan 15;113(3):679–87. doi:10.1182/blood-2008-05-155093 Garbowski MW, Bansal S, Porter JB, Mori C, Burckhardt S, Hider RC. Intravenous iron preparations transiently generate non-transferrin-bound iron from two proposed pathways.
521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 536	 19. 20. 21. 22. 23. 24. 	Alphandéry E. Iron oxide nanoparticles for therapeutic applications. Drug Discov Today. 2020 Jan;25(1):141–9. doi:10.1016/j.drudis.2019.09.020 Arami H, Khandhar A, Liggitt D, Krishnan KM. In vivo delivery, pharmacokinetics, biodistribution and toxicity of iron oxide nanoparticles. Chem Soc Rev. 2015 Dec 7;44(23):8576–607. doi:10.1039/c5cs00541h Rouault T, Klausner R. Regulation of iron metabolism in eukaryotes. Current Topics in Cellular Regulation. 1997 Jan 1;35:1–19. doi:10.1016/s0070-2137(97)80001-5 Cohen LA, Gutierrez L, Weiss A, Leichtmann-Bardoogo Y, Zhang D, Crooks DR, et al. Serum ferritin is derived primarily from macrophages through a nonclassical secretory pathway. Blood. 2010 Sep 2;116(9):1574–84. doi:10.1182/blood-2009-11-253815 Ferring-Appel D, Hentze MW, Galy B. Cell-autonomous and systemic context-dependent functions of iron regulatory protein 2 in mammalian iron metabolism. Blood. 2009 Jan 15;113(3):679–87. doi:10.1182/blood-2008-05-155093 Garbowski MW, Bansal S, Porter JB, Mori C, Burckhardt S, Hider RC. Intravenous iron preparations transiently generate non-transferrin-bound iron from two proposed pathways. Haematologica. 2020 Nov 1;106(11):2885–96. doi:10.3324/haematol.2020.250803
521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 536 537	 19. 20. 21. 22. 23. 24. 25. 	 Alphandéry E. Iron oxide nanoparticles for therapeutic applications. Drug Discov Today. 2020 Jan;25(1):141–9. doi:10.1016/j.drudis.2019.09.020 Arami H, Khandhar A, Liggitt D, Krishnan KM. In vivo delivery, pharmacokinetics, biodistribution and toxicity of iron oxide nanoparticles. Chem Soc Rev. 2015 Dec 7;44(23):8576–607. doi:10.1039/c5cs00541h Rouault T, Klausner R. Regulation of iron metabolism in eukaryotes. Current Topics in Cellular Regulation. 1997 Jan 1;35:1–19. doi:10.1016/s0070-2137(97)80001-5 Cohen LA, Gutierrez L, Weiss A, Leichtmann-Bardoogo Y, Zhang D, Crooks DR, et al. Serum ferritin is derived primarily from macrophages through a nonclassical secretory pathway. Blood. 2010 Sep 2;116(9):1574–84. doi:10.1182/blood-2009-11-253815 Ferring-Appel D, Hentze MW, Galy B. Cell-autonomous and systemic context-dependent functions of iron regulatory protein 2 in mammalian iron metabolism. Blood. 2009 Jan 15;113(3):679–87. doi:10.1182/blood-2008-05-155093 Garbowski MW, Bansal S, Porter JB, Mori C, Burckhardt S, Hider RC. Intravenous iron preparations transiently generate non-transferrin-bound iron from two proposed pathways. Haematologica. 2020 Nov 1;106(11):2885–96. doi:10.3324/haematol.2020.250803 Knutson MD. Non-transferrin-bound iron transporters. Free Radic Biol Med. 2019
520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 533 534 535 536 537 538	 19. 20. 21. 22. 23. 24. 25. 	Alphandéry E. Iron oxide nanoparticles for therapeutic applications. Drug Discov Today. 2020 Jan;25(1):141–9. doi:10.1016/j.drudis.2019.09.020 Arami H, Khandhar A, Liggitt D, Krishnan KM. In vivo delivery, pharmacokinetics, biodistribution and toxicity of iron oxide nanoparticles. Chem Soc Rev. 2015 Dec 7;44(23):8576–607. doi:10.1039/c5cs00541h Rouault T, Klausner R. Regulation of iron metabolism in eukaryotes. Current Topics in Cellular Regulation. 1997 Jan 1;35:1–19. doi:10.1016/s0070-2137(97)80001-5 Cohen LA, Gutierrez L, Weiss A, Leichtmann-Bardoogo Y, Zhang D, Crooks DR, et al. Serum ferritin is derived primarily from macrophages through a nonclassical secretory pathway. Blood. 2010 Sep 2;116(9):1574–84. doi:10.1182/blood-2009-11-253815 Ferring-Appel D, Hentze MW, Galy B. Cell-autonomous and systemic context-dependent functions of iron regulatory protein 2 in mammalian iron metabolism. Blood. 2009 Jan 15;113(3):679–87. doi:10.1182/blood-2008-05-155093 Garbowski MW, Bansal S, Porter JB, Mori C, Burckhardt S, Hider RC. Intravenous iron preparations transiently generate non-transferrin-bound iron from two proposed pathways. Haematologica. 2020 Nov 1;106(11):2885–96. doi:10.3324/haematol.2020.250803 Knutson MD. Non-transferrin-bound iron transporters. Free Radic Biol Med. 2019 Mar;133:101–11. doi:10.1016/j.freeradbiomed.2018.10.413
520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 532 533 534 535 536 537 538 539	 19. 20. 21. 22. 23. 24. 25. 26. 	 Alphandéry E. Iron oxide nanoparticles for therapeutic applications. Drug Discov Today. 2020 Jan;25(1):141–9. doi:10.1016/j.drudis.2019.09.020 Arami H, Khandhar A, Liggitt D, Krishnan KM. In vivo delivery, pharmacokinetics, biodistribution and toxicity of iron oxide nanoparticles. Chem Soc Rev. 2015 Dec 7;44(23):8576–607. doi:10.1039/c5cs00541h Rouault T, Klausner R. Regulation of iron metabolism in eukaryotes. Current Topics in Cellular Regulation. 1997 Jan 1;35:1–19. doi:10.1016/s0070-2137(97)80001-5 Cohen LA, Gutierrez L, Weiss A, Leichtmann-Bardoogo Y, Zhang D, Crooks DR, et al. Serum ferritin is derived primarily from macrophages through a nonclassical secretory pathway. Blood. 2010 Sep 2;116(9):1574–84. doi:10.1182/blood-2009-11-253815 Ferring-Appel D, Hentze MW, Galy B. Cell-autonomous and systemic context-dependent functions of iron regulatory protein 2 in mammalian iron metabolism. Blood. 2009 Jan 15;113(3):679–87. doi:10.1182/blood-2008-05-155093 Garbowski MW, Bansal S, Porter JB, Mori C, Burckhardt S, Hider RC. Intravenous iron preparations transiently generate non-transferrin-bound iron from two proposed pathways. Haematologica. 2020 Nov 1;106(11):2885–96. doi:10.3324/haematol.2020.250803 Knutson MD. Non-transferrin-bound iron transporters. Free Radic Biol Med. 2019 Mar;133:101–11. doi:10.1016/j.freeradbiomed.2018.10.413 Oudit GY, Sun H, Trivieri MG, Koch SE, Dawood F, Ackerley C, et al. L-type Ca2+ channels
520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540	 19. 20. 21. 22. 23. 24. 25. 26. 	Alphandéry E. Iron oxide nanoparticles for therapeutic applications. Drug Discov Today. 2020 Jan;25(1):141–9. doi:10.1016/j.drudis.2019.09.020 Arami H, Khandhar A, Liggitt D, Krishnan KM. In vivo delivery, pharmacokinetics, biodistribution and toxicity of iron oxide nanoparticles. Chem Soc Rev. 2015 Dec 7;44(23):8576–607. doi:10.1039/c5cs00541h Rouault T, Klausner R. Regulation of iron metabolism in eukaryotes. Current Topics in Cellular Regulation. 1997 Jan 1;35:1–19. doi:10.1016/s0070-2137(97)80001-5 Cohen LA, Gutierrez L, Weiss A, Leichtmann-Bardoogo Y, Zhang D, Crooks DR, et al. Serum ferritin is derived primarily from macrophages through a nonclassical secretory pathway. Blood. 2010 Sep 2;116(9):1574–84. doi:10.1182/blood-2009-11-253815 Ferring-Appel D, Hentze MW, Galy B. Cell-autonomous and systemic context-dependent functions of iron regulatory protein 2 in mammalian iron metabolism. Blood. 2009 Jan 15;113(3):679–87. doi:10.1182/blood-2008-05-155093 Garbowski MW, Bansal S, Porter JB, Mori C, Burckhardt S, Hider RC. Intravenous iron preparations transiently generate non-transferrin-bound iron from two proposed pathways. Haematologica. 2020 Nov 1;106(11):2885–96. doi:10.3324/haematol.2020.250803 Knutson MD. Non-transferrin-bound iron transporters. Free Radic Biol Med. 2019 Mar;133:101–11. doi:10.1016/j.freeradbiomed.2018.10.413 Oudit GY, Sun H, Trivieri MG, Koch SE, Dawood F, Ackerley C, et al. L-type Ca2+ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload
520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 532 533 534 535 536 537 538 539 539 540 541	 19. 20. 21. 22. 23. 24. 25. 26. 	Alphandéry E. Iron oxide nanoparticles for therapeutic applications. Drug Discov Today. 2020 Jan;25(1):141–9. doi:10.1016/j.drudis.2019.09.020 Arami H, Khandhar A, Liggitt D, Krishnan KM. In vivo delivery, pharmacokinetics, biodistribution and toxicity of iron oxide nanoparticles. Chem Soc Rev. 2015 Dec 7;44(23):8576–607. doi:10.1039/c5cs00541h Rouault T, Klausner R. Regulation of iron metabolism in eukaryotes. Current Topics in Cellular Regulation. 1997 Jan 1;35:1–19. doi:10.1016/s0070-2137(97)80001-5 Cohen LA, Gutierrez L, Weiss A, Leichtmann-Bardoogo Y, Zhang D, Crooks DR, et al. Serum ferritin is derived primarily from macrophages through a nonclassical secretory pathway. Blood. 2010 Sep 2;116(9):1574–84. doi:10.1182/blood-2009-11-253815 Ferring-Appel D, Hentze MW, Galy B. Cell-autonomous and systemic context-dependent functions of iron regulatory protein 2 in mammalian iron metabolism. Blood. 2009 Jan 15;113(3):679–87. doi:10.1182/blood-2008-05-155093 Garbowski MW, Bansal S, Porter JB, Mori C, Burckhardt S, Hider RC. Intravenous iron preparations transiently generate non-transferrin-bound iron from two proposed pathways. Haematologica. 2020 Nov 1;106(11):2885–96. doi:10.3324/haematol.2020.250803 Knutson MD. Non-transferrin-bound iron transporters. Free Radic Biol Med. 2019 Mar;133:101–11. doi:10.1016/j.freeradbiomed.2018.10.413 Oudit GY, Sun H, Trivieri MG, Koch SE, Dawood F, Ackerley C, et al. L-type Ca2+ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy. Nat Med. 2003 Sep 1;9(9):1187–94. doi:10.1038/nm920
520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 532 533 534 535 536 537 538 539 540 541 542	 19. 20. 21. 22. 23. 24. 25. 26. 27. 	Alphandéry E. Iron oxide nanoparticles for therapeutic applications. Drug Discov Today. 2020 Jan;25(1):141–9. doi:10.1016/j.drudis.2019.09.020 Arami H, Khandhar A, Liggitt D, Krishnan KM. In vivo delivery, pharmacokinetics, biodistribution and toxicity of iron oxide nanoparticles. Chem Soc Rev. 2015 Dec 7;44(23):8576–607. doi:10.1039/c5cs00541h Rouault T, Klausner R. Regulation of iron metabolism in eukaryotes. Current Topics in Cellular Regulation. 1997 Jan 1;35:1–19. doi:10.1016/s0070-2137(97)80001-5 Cohen LA, Gutierrez L, Weiss A, Leichtmann-Bardoogo Y, Zhang D, Crooks DR, et al. Serum ferritin is derived primarily from macrophages through a nonclassical secretory pathway. Blood. 2010 Sep 2;116(9):1574–84. doi:10.1182/blood-2009-11-253815 Ferring-Appel D, Hentze MW, Galy B. Cell-autonomous and systemic context-dependent functions of iron regulatory protein 2 in mammalian iron metabolism. Blood. 2009 Jan 15;113(3):679–87. doi:10.1182/blood-2008-05-155093 Garbowski MW, Bansal S, Porter JB, Mori C, Burckhardt S, Hider RC. Intravenous iron preparations transiently generate non-transferrin-bound iron from two proposed pathways. Haematologica. 2020 Nov 1;106(11):2885–96. doi:10.3324/haematol.2020.250803 Knutson MD. Non-transferrin-bound iron transporters. Free Radic Biol Med. 2019 Mar;133:101–11. doi:10.1016/j.freeradbiomed.2018.10.413 Oudit GY, Sun H, Trivieri MG, Koch SE, Dawood F, Ackerley C, et al. L-type Ca2+ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy. Nat Med. 2003 Sep 1;9(9):1187–94. doi:10.1038/nm920 Kumfu S, Chattipakorn S, Chinda K, Fucharoen S, Chattipakorn N. T-tvpe calcium channel
520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 532 533 534 535 536 537 538 539 538 539 540 541 542 543	 19. 20. 21. 22. 23. 24. 25. 26. 27. 	Alphandéry E. Iron oxide nanoparticles for therapeutic applications. Drug Discov Today. 2020 Jan;25(1):141–9. doi:10.1016/j.drudis.2019.09.020 Arami H, Khandhar A, Liggitt D, Krishnan KM. In vivo delivery, pharmacokinetics, biodistribution and toxicity of iron oxide nanoparticles. Chem Soc Rev. 2015 Dec 7;44(23):8576–607. doi:10.1039/c5cs00541h Rouault T, Klausner R. Regulation of iron metabolism in eukaryotes. Current Topics in Cellular Regulation. 1997 Jan 1;35:1–19. doi:10.1016/s0070-2137(97)80001-5 Cohen LA, Gutierrez L, Weiss A, Leichtmann-Bardoogo Y, Zhang D, Crooks DR, et al. Serum ferritin is derived primarily from macrophages through a nonclassical secretory pathway. Blood. 2010 Sep 2;116(9):1574–84. doi:10.1182/blood-2009-11-253815 Ferring-Appel D, Hentze MW, Galy B. Cell-autonomous and systemic context-dependent functions of iron regulatory protein 2 in mammalian iron metabolism. Blood. 2009 Jan 15;113(3):679–87. doi:10.1182/blood-2008-05-155093 Garbowski MW, Bansal S, Porter JB, Mori C, Burckhardt S, Hider RC. Intravenous iron preparations transiently generate non-transferrin-bound iron from two proposed pathways. Haematologica. 2020 Nov 1;106(11):2885–96. doi:10.3324/haematol.2020.250803 Knutson MD. Non-transferrin-bound iron transporters. Free Radic Biol Med. 2019 Mar;133:101–11. doi:10.1016/j.freeradbiomed.2018.10.413 Oudit GY, Sun H, Trivieri MG, Koch SE, Dawood F, Ackerley C, et al. L-type Ca2+ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy. Nat Med. 2003 Sep 1;9(9):1187–94. doi:10.1038/nm920 Kumfu S, Chattipakorn S, Chinda K, Fucharoen S, Chattipakorn N. T-type calcium channel blockade improves survival and cardiovascular function in thalassemic mice. Eur J Haematol.
521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 536 537 538 537 538 539 540 541 542 543 544	 19. 20. 21. 22. 23. 24. 25. 26. 27. 	Alphandéry E. Iron oxide nanoparticles for therapeutic applications. Drug Discov Today. 2020 Jan;25(1):141–9. doi:10.1016/j.drudis.2019.09.020 Arami H, Khandhar A, Liggitt D, Krishnan KM. In vivo delivery, pharmacokinetics, biodistribution and toxicity of iron oxide nanoparticles. Chem Soc Rev. 2015 Dec 7;44(23):8576–607. doi:10.1039/c5cs00541h Rouault T, Klausner R. Regulation of iron metabolism in eukaryotes. Current Topics in Cellular Regulation. 1997 Jan 1;35:1–19. doi:10.1016/s0070-2137(97)80001-5 Cohen LA, Gutierrez L, Weiss A, Leichtmann-Bardoogo Y, Zhang D, Crooks DR, et al. Serum ferritin is derived primarily from macrophages through a nonclassical secretory pathway. Blood. 2010 Sep 2;116(9):1574–84. doi:10.1182/blood-2009-11-253815 Ferring-Appel D, Hentze MW, Galy B. Cell-autonomous and systemic context-dependent functions of iron regulatory protein 2 in mammalian iron metabolism. Blood. 2009 Jan 15;113(3):679–87. doi:10.1182/blood-2008-05-155093 Garbowski MW, Bansal S, Porter JB, Mori C, Burckhardt S, Hider RC. Intravenous iron preparations transiently generate non-transferrin-bound iron from two proposed pathways. Haematologica. 2020 Nov 1;106(11):2885–96. doi:10.3324/haematol.2020.250803 Knutson MD. Non-transferrin-bound iron transporters. Free Radic Biol Med. 2019 Mar;133:101–11. doi:10.1016/j.freeradbiomed.2018.10.413 Oudit GY, Sun H, Trivieri MG, Koch SE, Dawood F, Ackerley C, et al. L-type Ca2+ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy. Nat Med. 2003 Sep 1;9(9):1187–94. doi:10.1038/nm920 Kumfu S, Chattipakorn S, Chinda K, Fucharoen S, Chattipakorn N. T-type calcium channel blockade improves survival and cardiovascular function in thalassemic mice. Eur J Haematol. 2012 Jun;88(6):535–48. doi:10.1111/j.1600-0609.2012.01779.x

	~ ~	
545	28.	Powell LW, Alpert E, Isselbacher KJ, Drysdale JW. Human Isoferritins: Organ Specific Iron and
546		Apoferritin Distribution. Br J Haematol. 1975 May;30(1):47–55. doi:10.1111/j.1365-
547		2141.1975.tb00516.x
548	29.	Srivastava AK, Reutovich AA, Hunter NJ, Arosio P, Bou-Abdallah F. Ferritin
549		microheterogeneity, subunit composition, functional, and physiological implications. Sci Rep.
550		2023 Nov 14;13(1):19862. doi:10.1038/s41598-023-46880-9
551	30.	Udani K. Chris-Olaiva A. Ohadugha C. Malik A. Sansbury J. Paari D. Cardiovascular
552		manifestations in hospitalized patients with hemochromatosis in the United States. Int I
552		Cardiol 2021 Nov 1:342:117–24. doi:10.1016/i.jicard 2021.07.060
555	21	Massraghli DB, Moon IC, Forreira VM, Grosse Wortmann I, He T, Kellman B, Massherbauer
554	51.	L Nozofat D. Solorno M. Scholhort ED. Toulor AL Thompson D. Ligondor M. von Llosswiik DD.
555		J, Nezalat K, Salemo IVI, Scheidert EB, Taylor AJ, mompson K, Ogander IVI, Van Heeswijk KB,
550		Friedrich MG. Clinical recommendations for cardiovascular magnetic resonance mapping of
557		11, 12, 12* and extracellular volume: A consensus statement by the Society for
558		Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for
559		Cardiovascular Imaging (EACVI). J Cardiovasc Magn Reson. 2017 Oct 9;19(1):75. doi:
560		10.1186/s12968-017-0389-8. Erratum in: J Cardiovasc Magn Reson. 2018 Feb 7;20(1):9.
561	32.	Aron AT, Heffern MC, Lonergan ZR, Vander Wal MN, Blank BR, Spangler B, et al. In vivo
562		bioluminescence imaging of labile iron accumulation in a murine model of Acinetobacter
563		baumannii infection. Proc Natl Acad Sci U S A. 2017 Nov 28;114(48):12669–74.
564		doi:10.1073/pnas.1708747114
565	33.	Lagan J, Naish JH, Simpson K, Zi M, Cartwright EJ, Foden P, Morris J, Clark D, Birchall L,
566		Caldwell J, Trafford A, Fortune C, Cullen M, Chaudhuri N, Fildes J, Sarma J, Schelbert EB,
567		Schmitt M, Piper Hanley K, Miller CA. Substrate for the Myocardial Inflammation-Heart
568		Failure Hypothesis Identified Using Novel USPIO Methodology, JACC Cardiovasc Imaging.
569		2021 Feb:14(2):365-376. doi: 10.1016/i.jcmg.2020.02.001
570	34	Piechnik SK, Ferreira VM, Dall'Armellina F, Cochlin J F, Greiser A, Neubauer S, Robson MD
570	51.	Shortened Modified Look-Locker Inversion recovery (ShMOLLI) for clinical myocardial T1-
572		manning at 1.5 and 3.T within a 9 heartheat hreathhold I Cardiovasc Magn Reson, 2010 Nov
572		10·12/1)·60 doi: 10.1186/1522-420V-12-60
575	25	7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7
574	55.	Zhang Q, Werys K, Popescu IA, Blasioni L, Ntusi NAB, Desai W, Zimmerman SL, Shan DJ, Autry
5/5		K, KIM B, KIM HW, Jenista ER, Huber S, White JA, Miccann GP, Monidum SA, Boubertakn R,
5/6		Chiribiri A, Newby D, Prasad S, Radjenović A, Dawson D, Schulz-Menger J, Manrholdt H,
577		Carbone I, Rimoldi O, Colagrande S, Calistri L, Michels M, Hofman MBM, Anderson L, Broberg
578		C, Andrew F, Sanz J, Bucciarelli-Ducci C, Chow K, Higgins D, Broadbent DA, Semple S, Hafyane
579		T, Wormleighton J, Salerno M, He T, Plein S, Kwong RY, Jerosch-Herold M, Kramer CM,
580		Neubauer S, Ferreira VM, Piechnik SK. Quality assurance of quantitative cardiac T1-mapping
581		in multicenter clinical trials - A T1 phantom program from the hypertrophic cardiomyopathy
582		registry (HCMR) study. Int J Cardiol. 2021 May 1;330:251-258. doi:
583		10.1016/j.ijcard.2021.01.026.
584	36.	Cao Y-A, Wagers AJ, Beilhack A, Dusich J, Bachmann MH, Negrin RS, et al. Shifting foci of
585		hematopoiesis during reconstitution from single stem cells. Proc Natl Acad Sci U S A. 2004
586		Jan 6;101(1):221–6. doi:10.1073/pnas.2637010100
587	37.	Lakhal-Littleton S, Wolna M, Carr CA, Miller JJJ, Christian HC. Ball V. et al. Cardiac ferroportin
588	•	regulates cellular iron homeostasis and is important for cardiac function. Proc Natl Acad Sci
589		U S A. 2015 Mar 10:112(10):3164–9. doi:10.1073/pnas.1422373112
590	38	Jacobs FMG Hendriks ICM van Tits BLIH Evans PL Brouer W. Liu DV et al. Results of an
501	50.	international round robin for the quantification of corum non-transform hound iron. Mood
JAT		

592		for defining standardization and a clinically relevant isoform. Anal Biochem. 2005 Jun
593		15;341(2):241–50. doi:10.1016/j.ab.2005.03.008
594	39.	Núñez J, Miñana G, Cardells I, Palau P, Llàcer P, Fácila L, Almenar L, López-Lereu MP,
595		Monmeneu JV, Amiguet M, González J, Serrano A, Montagud V, López-Vilella R, Valero E,
596		García-Blas S, Bodí V, de la Espriella-Juan R, Lupón J, Navarro J, Górriz JL, Sanchis J, Chorro FJ,
597		Comín-Colet J, Bayés-Genís A; Myocardial-IRON Investigators* +. Noninvasive Imaging
598		Estimation of Myocardial Iron Repletion Following Administration of Intravenous Iron: The
599		Myocardial-IRON Trial. J Am Heart Assoc. 2020 Feb 18;9(4):e014254. doi:
600		10.1161/JAHA.119.014254.
601	40.	Nemeth E, Ganz T. Hepcidin-Ferroportin Interaction Controls Systemic Iron Homeostasis. Int
602		J Mol Sci. 2021 Jun 17;22(12):6493. doi:10.3390/ijms22126493
603	41.	Meloni A, Martini N, Positano V, De Luca A, Pistoia L, Sbragi S, et al. Myocardial iron overload
604		by cardiovascular magnetic resonance native segmental T1 mapping: a sensitive approach
605		that correlates with cardiac complications. J Cardiovasc Magn Reson. 2021 Jun 14;23(1):70.
606		doi:10.1186/s12968-021-00765-w
607	42.	Torlasco C, Cassinerio E, Roghi A, Faini A, Capecchi M, Abdel-Gadir A, et al. Role of T1
608		mapping as a complementary tool to T2* for non-invasive cardiac iron overload assessment.
609		PLoS One. 2018 Feb 21;13(2):e0192890. doi:10.1371/journal.pone.0192890
610	43.	Theil EC. Ferritin: the protein nanocage and iron biomineral in health and in disease. Inorg
611	-	Chem. 2013:52(21):12223-12233. doi:10.1021/ic400484n
612	44.	Singh SP. Jagia P. Oiha V. Seth T. Naik N. Ganga KP. et al. Diagnostic Value of T1 Mapping in
613		Detecting Iron Overload in Indian Patients with Thalassemia Major: A Comparison with T2*
614		Mapping Indian Journal of Radiology and Imaging 2024:34(01):54–9 doi:10.1055/s-0043-
615		1772467
616	45.	Shand AW, Nassar N. Rapid increase in intravenous iron therapy for women of reproductive
617		age in Australia. Med J Aust. 2021 Apr;214(6):285-285.e1. doi: 10.5694/mja2.50979.
618	46.	Niepel D, Klag T, Malek NP, Wehkamp J. Practical guidance for the management of iron
619		deficiency in patients with inflammatory bowel disease. Therap Adv Gastroenterol. 2018 Apr
620		26;11:1756284818769074. doi: 10.1177/1756284818769074.
621	47.	Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V, McDonagh T,
622		Parkhomenko A, Tavazzi L, Levesque V, Mori C, Roubert B, Filippatos G, Ruschitzka F, Anker
623		SD; CONFIRM-HF Investigators. Beneficial effects of long-term intravenous iron therapy with
624		ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency [†] . Eur
625		Heart J. 2015 Mar 14;36(11):657-68. doi: 10.1093/eurheartj/ehu385.
626	48.	Kalra PR, Cleland JGF, Petrie MC, Thomson EA, Kalra PA, Squire IB, Ahmed FZ, Al-Mohammad
627		A, Cowburn PJ, Foley PWX, Graham FJ, Japp AG, Lane RE, Lang NN, Ludman AJ, Macdougall
628		IC. Pellicori P. Ray R. Robertson M. Seed A. Ford I: IRONMAN Study Group. Intravenous ferric
629		derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an
630		investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial, Lancet,
631		2022 Dec 17:400(10369):2199-2209. doi: 10.1016/S0140-6736(22)02083-9.
632	49.	Mentz RJ, Garg J, Rockhold FW, Butler J, De Pasquale CG, Ezekowitz JA, Lewis GD, O'Meara E,
633		Ponikowski P. Troughton RW. Wong YW. She L. Harrington J. Adamczyk R. Blackman N.
634		Hernandez AF: HEART-FID Investigators, Ferric Carboxymaltose in Heart Failure with Iron
635		Deficiency N Engl I Med. 2023 Sen 14:389(11):975-986. doi: 10.1056/NEIMoa2304968
636	50	Moon IC. Messroghli DR. Kellman P. Piechnik SK. Rohson MD. Ugander M. Gatebouse PD
637	20.	Arai AF. Friedrich MG. Neubauer S. Schulz-Menger I. Schelbert FR: Society for Cardiovascular
638		Magnetic Resonance Imaging: Cardiovascular Magnetic Resonance Working Group of the
639		European Society of Cardiology, Myocardial T1 manning and extracellular volume
		-a. opean boliet, of caraloog, infoculation in thisping and extractional volume

medRxiv preprint doi: https://doi.org/10.1101/2024.01.18.24301496; this version posted March 11, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-ND 4.0 International license .

- 640 quantification: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working 641 Group of the European Society of Cardiology consensus statement. J Cardiovasc Magn Reson. 2013 Oct 14;15(1):92. doi: 10.1186/1532-429X-15-92. 642
- 643

Figure legends 644

Figure1- Trial profile 645

646 Figure 2- Ferric carboxymaltose treatment in patients results in rapid and sustained rise in

myocardial iron. A) Schematic of study design. B) Longitudinal changes from baseline (0h) in 647 648 myocardial T1 (Δ T1) for each participant. C) Longitudinal changes from baseline in splenic T1 (Δ T1) for each participant, D) Longitudinal changes from baseline in liver T1 (Δ T1) for each participant. Per-649 650 participant longitudinal assessments of plasma iron (E), transferrin saturation Tsat (F), plasma non-651 transferrin-bound iron NTBI (G), plasma lipid peroxidation marker MDA (H), plasma ferritin (I), 652 plasma hepcidin (J), haemoglobin Hb (K), haematocrit HCT (L) and mean corpuscular volume MCV

653 (M).

654 Figure 3- Ferric carboxymaltose treatment in mice results in rapid and sustained rise in myocardial

655 labile iron pool LIP. A) Schematic of study design. ID=iron-deficient diet containing 5 parts per

million (ppm) iron. RD=replete diet containing 200ppm iron. ICL-1=iron-caged luciferin. Luc Tg mice 656

657 are transgenic for the luciferase gene. B) Average radiance in hearts of iron-deficient or iron replete 658 mice 1 hour or 42 days after intravenous infusion of saline or FCM (15mg/kg iron). Representative

- 659 luminescence images of hearts from each experimental group are also shown. C) Total elemental
- 660 iron concentration in the spleen. D) Total elemental iron concentration in the liver. E) Concentrations
- 661 of iron in serum, F) Transferrin saturation Tsat in serum, G) Concentrations of non-transferrin bound
- iron NTBI in serum. 662

663 Figure 4- Exposure to Ferric carboxymaltose raises cellular LIP in cardiac myocytes via NTBI

664 transporters. A) Schematic of study design using rat cardiac myocytes, expressing the luciferase

665 transgene . B) Average radiance in cardiac myocytes after 0.5h or 2h exposure to saline or FCM

666 (0.25mg/ml iron) in growth media. Luminescence of individual wells are shown in bottom panel. C)

Average radiance in cardiac myocytes after 1h exposure to saline, FCM (0.25mg/ml iron) alone, or in 667

- 668 combination with ebselen (DMT1 inhibitor) or efonidipine (L-type and T-type calcium channel 669 inhibitor). Luminescence of individual wells are shown in bottom panel D) NTBI concentration in
- 670 supernatants of cells exposed to saline or FCM (0.25mg/ml).
- 671

GRAPHICAL ABSTRACT



Figure 1











-B

Ţ

ο

ಹ

<u>___</u>

50·

å

ᅇᅝᆑᅇ

Figure 4



D

